TABLE 2.

Antiviral activities of SG85, rupintrivir, and pleconaril on the replication of reverse-engineered RV14_IC strains that contain mutations in the 3C^pro-encoding gene

RV14IC strain	EC50 (μM) ± MAD (RR)a
	SG85	Rupintrivir	Pleconaril
Wild type	0.018 ± 0.001	0.010 ± 0.001	0.327 ± 0.004
S127G mutant	0.019 ± 0.001 (1)	0.0094 ± 0.0002 (1)	0.31 ± 0.01 (1)
T143A mutant	0.018 ± 0.001 (1)	0.008 ± 0.001 (1)	0.108 ± 0.004b (0.3)
S127G T143A mutant	0.047 ± 0.001b (3)	0.012 ± 0.001 (1)	0.13 ± 0.02c (0.4)

^aAntiviral activity was determined in a CPE reduction assay with a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium readout. Data are in duplicate from three independent assays. The early-stage RV inhibitor pleconaril (kindly provided by V. Makarov, RAS Institute of Biochemistry, Russia) was included in this assay as a reference. MAD, median absolute deviation. RR, relative resistance (EC₅₀ of mutated strain/EC₅₀ of wild type).

^bP < 0.0001 (unpaired t test).

^cP < 0.001 (unpaired t test).